Home 2018-06-19T09:43:09+00:00
What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

Freeline secures over £88 million of funding

Freeline Therapeutics Ltd (“Freeline”), a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in a Series B financing round. Syncona Ltd (“Syncona”) led the new investment committing £85 million, with The UCL Technology Fund, committing £3.4 million to the series B funding. This augments the previous £33.5 million Series A investment from founding investor Syncona.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

Children are not small adults.

When it comes to the use of medicines, children cannot be treated as small adults.  Find out how our spinout, Therakind, is ensuring that children’s medicine used today is both safe and effective.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

/ UCLB News
Fortress Biotech, formerly Coronado Biosciences Inc, announces publication in the journal Biology of Blood and Marrow Transplantation of positive Phase ...

Freeline secures over £88 million of funding

/ UCLB News
London, 19 June 2018 – Freeline Therapeutics Ltd (“Freeline”), a clinical stage company focused on treatment of chronic systemic diseases with ...

UCL SPINOUT MEIRAGTX ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING

/ Spinout News, UCLB News
UCL Spinout MeiraGTx Holdings plc a vertically integrated, clinical stage gene therapy company, announced the closing of its initial public ...

UCL TECHNOLOGY FUND HAS APPROVED INVESTMENT OF UP TO £1M IN THE DEVELOPMENT OF A GENE THERAPY FOR (PERFORIN DEFICIENT) FAMILIAL HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

/ UCLB News
The UCL Technology Fund (UCLTF) has approved an investment of up to £1m to support Professor Bobby Gaspar’s development of ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2016
0
Drug discoveries
0
New patent applications